Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for P3 Health Partners (PIII) over the last 7 years, with Q3 2025 value amounting to $37.7 million.

  • P3 Health Partners' Cash & Equivalents fell 4010.04% to $37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.7 million, marking a year-over-year decrease of 4010.04%. This contributed to the annual value of $38.8 million for FY2024, which is 687.22% up from last year.
  • As of Q3 2025, P3 Health Partners' Cash & Equivalents stood at $37.7 million, which was down 4010.04% from $38.6 million recorded in Q2 2025.
  • P3 Health Partners' Cash & Equivalents' 5-year high stood at $110.3 million during Q1 2022, with a 5-year trough of $4.3 million in Q3 2021.
  • Its 5-year average for Cash & Equivalents is $39.4 million, with a median of $37.7 million in 2025.
  • As far as peak fluctuations go, P3 Health Partners' Cash & Equivalents soared by 69226.85% in 2022, and later tumbled by 9347.51% in 2023.
  • P3 Health Partners' Cash & Equivalents (Quarter) stood at $5.3 million in 2021, then surged by 230.82% to $17.5 million in 2022, then soared by 107.1% to $36.3 million in 2023, then rose by 6.87% to $38.8 million in 2024, then fell by 2.84% to $37.7 million in 2025.
  • Its last three reported values are $37.7 million in Q3 2025, $38.6 million for Q2 2025, and $40.1 million during Q1 2025.